Publications

British journal of cancer

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

16-11-2001

Journal of chromatography. B, Biomedical sciences and applications

Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.

05-11-2001

Journal of chromatography. B, Biomedical sciences and applications

Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

05-08-2001

Cancer chemotherapy and pharmacology

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.

01-04-2001

Anti-cancer drugs

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.

01-04-2001

Toxicology letters

The importance of drug-transporting P-glycoproteins in toxicology.

31-03-2001

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

01-12-2000

Anti-cancer drugs

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.

01-11-2000

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

01-11-2000

Anti-cancer drugs

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.

01-10-2000

Investigational new drugs

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

01-08-2000

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacokinetic study of oral paclitaxel.

01-06-2000

Drug metabolism and disposition: the biological fate of chemicals

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

01-03-2000

Investigational new drugs

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

11-11-1999

The Journal of clinical investigation

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

01-10-1999

British journal of cancer

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

01-09-1999

The Journal of pharmacology and experimental therapeutics

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

01-04-1999

Anti-cancer drugs

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.

01-01-1999

British journal of cancer

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

01-01-1999

Journal of chromatography. B, Biomedical sciences and applications

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

20-11-1998

Clinical cancer research : an official journal of the American Association for Cancer Research

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

01-10-1998

Anti-cancer drugs

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

01-09-1998

Journal of chromatography. B, Biomedical sciences and applications

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

07-08-1998

Pharmacological research

The pharmacological role of P-glycoprotein in the intestinal epithelium.

01-06-1998

Cancer research

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

01-06-1998

Cancer chemotherapy and pharmacology

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

02-04-1998

European journal of cancer (Oxford, England : 1990)

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

01-01-1998

Journal of pharmaceutical sciences

The functional role of P-glycoprotein in the blood-brain barrier.

01-08-1997

Proceedings of the National Academy of Sciences of the United States of America

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

15-04-1997

Proceedings of the National Academy of Sciences of the United States of America

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

04-03-1997

Cancer chemotherapy and pharmacology

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.

01-01-1997

British journal of cancer

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

01-01-1997

Journal of the National Cancer Institute

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

17-07-1996

Journal of chromatography. B, Biomedical applications

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

07-06-1996

Drug metabolism and disposition: the biological fate of chemicals

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

01-06-1996

Cancer research

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

01-05-1996

Cancer chemotherapy and pharmacology

Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.

01-01-1996

Anti-cancer drugs

Tissue distribution, metabolism and excretion of paclitaxel in mice.

01-01-1996

Journal of chromatography. B, Biomedical applications

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

15-12-1995

Journal of pharmaceutical and biomedical analysis

High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.

01-12-1995

Therapeutic drug monitoring

Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?

01-10-1995

Proceedings of the National Academy of Sciences of the United States of America

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

15-08-1995

Cancer chemotherapy and pharmacology

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

01-01-1995

Pharmacy world & science : PWS

Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.

10-06-1994

Cell

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

20-05-1994

Journal of chromatography

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

14-01-1994

Cancer chemotherapy and pharmacology

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

01-01-1994

Cancer chemotherapy and pharmacology

The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

01-01-1994

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.

Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.

The importance of drug-transporting P-glycoproteins in toxicology.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Phase I and pharmacokinetic study of oral paclitaxel.

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

The pharmacological role of P-glycoprotein in the intestinal epithelium.

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

The functional role of P-glycoprotein in the blood-brain barrier.

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.

Tissue distribution, metabolism and excretion of paclitaxel in mice.

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.

Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

This site uses cookies